Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus
Public ClinicalTrials.gov record NCT03920267. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects With Systemic Lupus Erythematosus
Study identification
- NCT ID
- NCT03920267
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 261 participants
Conditions and interventions
Conditions
Interventions
- BMS-986165 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 25, 2019
- Primary completion
- Mar 20, 2025
- Completion
- Mar 20, 2025
- Last update posted
- Mar 19, 2026
2019 – 2025
United States locations
- U.S. sites
- 25
- U.S. states
- 12
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0077 | Birmingham | Alabama | 35233-1913 | — |
| Local Institution - 0030 | El Cajon | California | 92020 | — |
| Local Institution - 0049 | Torrance | California | 90502 | — |
| Local Institution - 0074 | New Haven | Connecticut | 06520 | — |
| Local Institution - 0115 | Aventura | Florida | 33180 | — |
| Local Institution - 0044 | Brandon | Florida | 33511 | — |
| Local Institution - 0140 | Gainesville | Florida | 32603 | — |
| Local Institution - 0133 | Orlando | Florida | 32835 | — |
| Local Institution - 0032 | Ormond Beach | Florida | 32174-1139 | — |
| Local Institution - 0048 | Tampa | Florida | 33613 | — |
| Local Institution - 0094 | Atlanta | Georgia | 30303 | — |
| Local Institution - 0050 | Lawrenceville | Georgia | 30046 | — |
| Local Institution - 0123 | Brooklyn | New York | 11201 | — |
| Local Institution - 0131 | New York | New York | 10016 | — |
| Local Institution - 0071 | Chapel Hill | North Carolina | 27599-7280 | — |
| Local Institution - 0031 | Charlotte | North Carolina | 28204 | — |
| Local Institution - 0064 | Oklahoma City | Oklahoma | 73104 | — |
| Local Institution - 0035 | Wyomissing | Pennsylvania | 19610 | — |
| Local Institution - 0121 | Charleston | South Carolina | 29425 | — |
| Local Institution - 0001 | Jackson | Tennessee | 38305 | — |
| Local Institution - 0041 | Austin | Texas | 78731-3146 | — |
| Tekton Research - Austin | Austin | Texas | 78745 | — |
| Local Institution - 0114 | Dallas | Texas | 75390 | — |
| Local Institution - 0037 | Houston | Texas | 77084 | — |
| Local Institution - 0046 | Mesquite | Texas | 75150 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 73 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03920267, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 19, 2026 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03920267 live on ClinicalTrials.gov.